Andreas Kiesbye Øvlisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Kiesbye Øvlisen has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Marianne Tang Severinsen
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
8 shared publications - Tarec Christoffer El-Galaly
Department of Hematology Aarhus University Hospital Aarhus Denmark
7 shared publications - Ingrid Glimelius
Uppsala University, Uppsala, Sweden
5 shared publications Karin E. Smedby
Clinical Epidemiology Division, Department of Medicine Solna Karolinska Institutet Stockholm Sweden
4 shared publications- Lasse Hjort Jakobsen
Department of Hematology, Aalborg University Hospital, Aalborg, Denmark
4 shared publications - Sandra Eloranta
Division of Clinical Epidemiology, Department of Medicine Solna Karolinska Institutet Stockholm Sweden
4 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (11)
Elevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.
- 15 November 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (11)
Open AccessElevated Risk of Psychotropic Drug Prescriptions in Adults With Mastocytosis: A Danish Matched Cohort Study
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.
- Open Access
- 3 January 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (1) , 43-53
Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study
Introduction: Mastocytosis is a group of rare heterogeneous diseases with a prevalence previously found to be 10–23 per 100,000 persons. More awareness and improvements in the diagnostic methods in later years have led to more patients being diagnosed. Here, we set out to present the prevalence and incidence rate of mastocytosis among the adult Danish population. By merging data from the Danish National Patient Register, the Danish Pathology Register and the Danish Cancer Register we included all adult patients (≥ 18 years) diagnosed with mastocytosis in Denmark prior to 2022. A cohort of 1,594 patients with mastocytosis was identified. The prevalence of mastocytosis was 27.43 per 100,000 persons (95% confidence interval [CI]: 25.95–28.96) as of January 1, 2022, and the 25-year average incidence rate between 1997 and 2021 was 1.21 per 100,000 persons (95%CI: 1.02–1.40) with an increasing incidence rate since 2002. We found a higher prevalence of mastocytosis among adults in the Danish population than previously reported, and an increasing incidence rate during the last 20 years. Increased awareness of the disease and better diagnostic methods most likely contributed to this.
- 3 January 2025
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 40 (1) , 43-53
Open AccessPrevalence and incidence of mastocytosis in adults: a Danish nationwide register study
Introduction: Mastocytosis is a group of rare heterogeneous diseases with a prevalence previously found to be 10–23 per 100,000 persons. More awareness and improvements in the diagnostic methods in later years have led to more patients being diagnosed. Here, we set out to present the prevalence and incidence rate of mastocytosis among the adult Danish population. By merging data from the Danish National Patient Register, the Danish Pathology Register and the Danish Cancer Register we included all adult patients (≥ 18 years) diagnosed with mastocytosis in Denmark prior to 2022. A cohort of 1,594 patients with mastocytosis was identified. The prevalence of mastocytosis was 27.43 per 100,000 persons (95% confidence interval [CI]: 25.95–28.96) as of January 1, 2022, and the 25-year average incidence rate between 1997 and 2021 was 1.21 per 100,000 persons (95%CI: 1.02–1.40) with an increasing incidence rate since 2002. We found a higher prevalence of mastocytosis among adults in the Danish population than previously reported, and an increasing incidence rate during the last 20 years. Increased awareness of the disease and better diagnostic methods most likely contributed to this.
- Open Access
- 26 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5932-5934
The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes
- 26 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5932-5934
Open AccessThe use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes
- Open Access
- 29 April 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 542-551
Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study
Summary: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population‐based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age‐ and sex‐matched comparators from the background population. Median follow‐up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30–3.68]), with a 10‐year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35–26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43–2.76]), with a 10‐year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43–1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B‐symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work‐up of pulmonary symptoms.
- 29 April 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 542-551
Open AccessPulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: A Danish national cohort study
Summary: Late toxicities can impact survivorship in patients with classical Hodgkin lymphoma (cHL) with pulmonary toxicity after bleomycin‐containing chemotherapy being a concern. The incidence of pulmonary diseases was examined in this Danish population‐based study. A total of 1474 adult patients with cHL treated with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or BEACOPP (bleomycin, vincristine, etoposide, doxorubicin, cyclophosphamide, procarbazine and prednisone) between 2000 and 2018 were included along with 7370 age‐ and sex‐matched comparators from the background population. Median follow‐up was 8.6 years for the patients. Patients with cHL had increased risk of incident pulmonary diseases (HR 2.91 [95% CI 2.30–3.68]), with a 10‐year cumulative risk of 7.4% versus 2.9% for comparators. Excess risks were observed for interstitial lung diseases (HR 15.84 [95% CI 9.35–26.84]) and chronic obstructive pulmonary disease (HR 1.99 [95% CI 1.43–2.76]), with a 10‐year cumulative risk of 4.1% and 3.5% respectively for patients. No excess risk was observed for asthma (HR 0.82 [95% CI 0.43–1.56]). Risk factors for interstitial lung diseases were age ≥60 years, the presence of B‐symptoms and low albumin. These findings document a significant burden of pulmonary diseases among patients with cHL and emphasize the importance of diagnostic work‐up of pulmonary symptoms.
- Open Access
- 30 June 2023
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 12 (3) , 118-122
An Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in RB1
Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is an extremely rare B-cell lymphoma. The disease is typically indolent and treatment with splenectomy usually results in durable remissions. Here, we present a case of an extremely aggressive course of SDRPL with transformation to diffuse large B-cell lymphoma and multiple relapses immediately following cessation of immunochemotherapy. We provide results from whole-exome sequencing from debut of SDRPL and from following transformed stages and identified a novel somatic mutation in RB1 as the possible driver of this aggressive disease, which has not been reported earlier in SDRPL.
- 30 June 2023
- Published by Elmer Press, Inc. in Journal of Hematology
- Vol. 12 (3) , 118-122
Open AccessAn Aggressive Course of Transformed Splenic Diffuse Red Pulp Small B-Cell Lymphoma With Novel Somatic Loss-of-Function Mutation in RB1
Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is an extremely rare B-cell lymphoma. The disease is typically indolent and treatment with splenectomy usually results in durable remissions. Here, we present a case of an extremely aggressive course of SDRPL with transformation to diffuse large B-cell lymphoma and multiple relapses immediately following cessation of immunochemotherapy. We provide results from whole-exome sequencing from debut of SDRPL and from following transformed stages and identified a novel somatic mutation in RB1 as the possible driver of this aggressive disease, which has not been reported earlier in SDRPL.
- Open Access
- 16 June 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (4) , 785-795
Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study
Summary: Previous studies concerning reproductive patterns among non‐Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18–40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31–0.59, HRmale: 0.61, 95% CI: 0.47–0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48–1.04, HRmale: 0.94, 95% CI: 0.70–1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10‐year follow‐up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.
- 16 June 2023
- Published by Wiley in British Journal of Haematology
- Vol. 202 (4) , 785-795
Open AccessReproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study
Summary: Previous studies concerning reproductive patterns among non‐Hodgkin lymphoma (NHL) survivors are scarce and those available have reported conflicting results. Treatment regimens vary considerably between aggressive and indolent NHL and studies of reproductive patterns by subtypes are warranted. In this matched cohort study, we identified all NHL patients aged 18–40 years and diagnosed between 2000 and 2018 from the Swedish and Danish lymphoma registers, and the clinical database at Oslo University Hospital (n = 2090). Population comparators were matched on sex, birth year and country (n = 19 427). Hazard ratios (HRs) were estimated using Cox regression. Males and females diagnosed with aggressive lymphoma subtypes had lower childbirth rates (HRfemale: 0.43, 95% CI: 0.31–0.59, HRmale: 0.61, 95% CI: 0.47–0.78) than comparators during the first 3 years after diagnosis. For indolent lymphomas, childbirth rates were not significantly different from comparators (HRfemale: 0.71, 95% CI: 0.48–1.04, HRmale: 0.94, 95% CI: 0.70–1.27) during the same period. Childbirth rates reached those of comparators for all subtypes after 3 years but the cumulative incidence of childbirths was decreased throughout the 10‐year follow‐up for aggressive NHL. Children of NHL patients were more likely to be born following assisted reproductive technology than those of comparators, except for male indolent lymphoma patients. In conclusion, fertility counselling is particularly important for patients with aggressive NHL.
- Open Access
- 29 April 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (4) , 723-731
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study
Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18‐40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995‐2018, who were linked to national medical birth registers. Cox regression adjusted for stage, performance status, year, and age at diagnosis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) contrasting time to first childbirth by treatment groups (ABVD, 2‐4 BEACOPP, 6‐8 BEACOPP) up to 10 years after diagnosis. Overall, 74.8% of patients were treated with ABVD, 3.1% with 2‐4 BEACOPP and 11.2% with 6‐8 BEACOPP. Adjusted HRs comparing childbirth rates in individuals treated with 6‐8 BEACOPP, and 2‐4 BEACOPP to ABVD were 0.53 (CI: 0.36‐0.77) and 0.33 (CI: 0.12‐0.91) for males, and 0.91 (CI: 0.61‐1.34) and 0.38 (CI: 0.12‐1.21) for females. Cumulative incidence of childbirths after 10 years was 19.8% (CI: 14.5%‐27.0%) for males and 34.3% (CI: 25.8%‐45.6%) for females treated with 6‐8 BEACOPP. Proportions of children born after assisted reproductive technique (ART) treatments were 77.4% (CI: 60.2‐88.6%) for males following 6‐8 BEACOPP, and <11% for females. Among ABVD treated patients the corresponding proportions were 12.2% (CI: 8.5%‐17.3%) and 10.6% (CI: 7.4%‐14.9%). BEACOPP treatment is associated with decreased childbirth rates compared to ABVD in male, but not female, cHL patients, despite widespread access to ART in the Nordics.
- 29 April 2023
- Published by Wiley in International Journal of Cancer
- Vol. 153 (4) , 723-731
Open AccessReproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study
Childbirth rates in classical Hodgkin lymphoma (cHL) survivors have historically been reduced compared to the general population. Understanding if contemporary treatment protocols are associated with reduced fertility is crucial as treatment guidelines shift toward more liberal use of intensive chemotherapy. We identified 2834 individuals aged 18‐40 years with cHL in Swedish and Danish lymphoma registers, and in the clinical database at Oslo University Hospital diagnosed 1995‐2018, who were linked to national medical birth registers. Cox regression adjusted for stage, performance status, year, and age at diagnosis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) contrasting time to first childbirth by treatment groups (ABVD, 2‐4 BEACOPP, 6‐8 BEACOPP) up to 10 years after diagnosis. Overall, 74.8% of patients were treated with ABVD, 3.1% with 2‐4 BEACOPP and 11.2% with 6‐8 BEACOPP. Adjusted HRs comparing childbirth rates in individuals treated with 6‐8 BEACOPP, and 2‐4 BEACOPP to ABVD were 0.53 (CI: 0.36‐0.77) and 0.33 (CI: 0.12‐0.91) for males, and 0.91 (CI: 0.61‐1.34) and 0.38 (CI: 0.12‐1.21) for females. Cumulative incidence of childbirths after 10 years was 19.8% (CI: 14.5%‐27.0%) for males and 34.3% (CI: 25.8%‐45.6%) for females treated with 6‐8 BEACOPP. Proportions of children born after assisted reproductive technique (ART) treatments were 77.4% (CI: 60.2‐88.6%) for males following 6‐8 BEACOPP, and <11% for females. Among ABVD treated patients the corresponding proportions were 12.2% (CI: 8.5%‐17.3%) and 10.6% (CI: 7.4%‐14.9%). BEACOPP treatment is associated with decreased childbirth rates compared to ABVD in male, but not female, cHL patients, despite widespread access to ART in the Nordics.
- Open Access
- 3 October 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 30
T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
- 3 October 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 30
Open AccessT065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
- Open Access
- 29 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (6) , 749-761
Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators
Psychological distress following cancer diagnosis may lead to mental health complications including depression and anxiety. Non‐Hodgkin lymphomas (NHLs) include indolent and aggressive subtypes for which treatment and prognosis differ widely. Incident use of psychotropic drugs (PDs—antidepressants, antipsychotics, and anxiolytics) and its correlation to lymphoma types can give insights into the psychological distress these patients endure. In this prospective matched cohort study, we used nationwide population‐based registries to investigate the cumulative risk of PD use in NHL patients compared to a sex‐ and age‐matched cohort from the Danish background population. In addition, contact patterns to psychiatric departments and incident intentional self‐harm or completed suicide were explored. In total, 8750 NHL patients and 43 750 matched comparators were included (median age 68; male:female ratio 1.6). Median follow‐up was 7.1 years. Two‐year cumulative risk of PD use was higher in NHL patients (16.4%) as compared to the matched comparators (5.1%, p < .01); patients with aggressive NHL subtypes had the highest incidence. Prescription rates were higher in the first years after diagnosis but approached the rate of the matched population 5 years into survivorship in aggressive NHLs, whereas patients with indolent subtypes continued to be at higher risk. NHL patients had a slightly higher two‐year risk of suicide/intentional self‐harm (0.3%) as compared to the matched comparators (0.2%, p = .01). These results demonstrate that mental health complications among NHL patients are frequent. Routine assessment for symptoms of depression and anxiety should be consider as part of standard follow‐up of NHL patients.
- 29 March 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (6) , 749-761
Open AccessMental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators
Psychological distress following cancer diagnosis may lead to mental health complications including depression and anxiety. Non‐Hodgkin lymphomas (NHLs) include indolent and aggressive subtypes for which treatment and prognosis differ widely. Incident use of psychotropic drugs (PDs—antidepressants, antipsychotics, and anxiolytics) and its correlation to lymphoma types can give insights into the psychological distress these patients endure. In this prospective matched cohort study, we used nationwide population‐based registries to investigate the cumulative risk of PD use in NHL patients compared to a sex‐ and age‐matched cohort from the Danish background population. In addition, contact patterns to psychiatric departments and incident intentional self‐harm or completed suicide were explored. In total, 8750 NHL patients and 43 750 matched comparators were included (median age 68; male:female ratio 1.6). Median follow‐up was 7.1 years. Two‐year cumulative risk of PD use was higher in NHL patients (16.4%) as compared to the matched comparators (5.1%, p < .01); patients with aggressive NHL subtypes had the highest incidence. Prescription rates were higher in the first years after diagnosis but approached the rate of the matched population 5 years into survivorship in aggressive NHLs, whereas patients with indolent subtypes continued to be at higher risk. NHL patients had a slightly higher two‐year risk of suicide/intentional self‐harm (0.3%) as compared to the matched comparators (0.2%, p = .01). These results demonstrate that mental health complications among NHL patients are frequent. Routine assessment for symptoms of depression and anxiety should be consider as part of standard follow‐up of NHL patients.